MLLT6 (myeloid/lymphoid or mixed-lineage leukemia translocated to 6) is a transcriptional regulator with histone-binding and chr17-remodeling activities that functions in gene expression regulation 1. The gene encodes a protein with an octapeptide motif and leucine-zipper dimerization domains 2, and its expression is regulated by sex hormones with demonstrated sex-specific phenotypic consequences 1. Mechanistically, MLLT6 maintains PD-L1 expression through interaction with the transcription factor ATF2, promoting an active chr17 structure that drives DDIT3/4 expression to facilitate cell apoptosis 34. MLLT6 depletion impairs STAT1 signaling and interferon-γ-responsive gene activation 4. Clinically, MLLT6 dysregulation contributes to multiple disease contexts. In hematological malignancies, MLLT6 serves as a recurrent fusion partner of KMT2A/MLL in acute myeloid leukemia and acute lymphoblastic leukemia 25. High MLLT6 expression predicts favorable breast cancer prognosis, with loss promoting metastatic progression 3. In ovarian cancer, elevated MLLT6 expression correlates with poor outcomes and paclitaxel resistance; MLLT6 knockdown enhances chemotherapy sensitivity 6. Additionally, MLLT6 downregulation has been implicated in neurodevelopmental disease with female preponderance 1.